HOLX250117P75000
- 3.60
- -0.02-0.55%
Hologic Newsroom
Needham Maintains Hologic(HOLX.US) With Buy Rating, Maintains Target Price $90
Positive Outlook for Hologic Amidst Revenue and EPS Adjustments: Analyst Recommends Buy
Here's Why Hologic (HOLX) Fell More Than Broader Market
Needham Reiterates Buy on Hologic, Maintains $90 Price Target
Hologic Agrees With CDC to Develop Reagents for H5N1 Bird Flu Testing
Peering Into Hologic's Recent Short Interest
FDA Announces Implantable Marker Recall: Hologic Removes BioZorb 3D Bioabsorbable Markers Due To Risk For Patient Complications
Express News | FDA: Identified Hologic's Recall as Most Serious Type; Recall Involves Removing Devices From Where They Are Used/Sold
Express News | FDA: There Have Been 252 Reported Injuries Related to Hologic's Biozorb 3D Bioabsorbable Markers
Express News | FDA: Hologic Removes Biozorb 3D Bioabsorbable Markers Due to Risk for Patient Complications
Express News | Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by Cdc
UBS Downgrades Hologic(HOLX.US) to Hold Rating, Cuts Target Price to $84
UBS Adjusts Price Target on Hologic to $84 From $90, Keeps Neutral Rating
Hologic Initiated With a Peer Perform at Wolfe Amid Near-term Headwinds
Hologic (HOLX) Stock Moves -1.93%: What You Should Know
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Wolfe Research Initiates Hologic(HOLX.US) With Hold Rating
Investors in Hologic (NASDAQ:HOLX) Have Seen Notable Returns of 44% Over the Past Five Years
Stephens Maintains Hologic(HOLX.US) With Buy Rating, Raises Target Price to $90
Morgan Stanley Maintains Hologic(HOLX.US) With Hold Rating, Maintains Target Price $84